Currently, the most prevalent immune checkpoint blockade approach in clinical tumor immunotherapy involves the use of anti-CTLA-4 or anti-PD-1/PD-L1 antibodies, either individually or in combination [35,36]. This evidence concerns the gene CTLA4 and neoplasm.